DJO Launches New EMPOWR 3D Knee Amid Growing Trend Toward Outpatient Total Joint Replacement

DJO Global Inc. launched its new EMPOWR 3D Knee in November amid the growing trend toward outpatient total joint replacement in younger and more active patients. Advanced implant sizing and modernized instrumentation compared with the legacy 3DKnee system should also drive higher surgeon adoption rates.

DJO Global Inc. launched the new EMPOWR 3D Knee in November at the American Association of Hip and Knee Surgeons 25th Annual Meeting in Dallas, TX. Capitalizing on the success of the original 3DKnee implant system launched in 2003, the EMPOWR 3D Knee preserves the same articular surface geometry; however, the instrumentation has been completely revamped and modernized. Like its predecessor, the EMPOWR 3D Knee targets younger patients with a higher activity level, “but the new implant is also very well suited for the typical, older, knee replacement patient,” says Miranda Jamieson, product director for the EMPOWR 3D Knee.

From a patient’s perspective, “we are offering a premium implant that provides the ability to restore a normal feeling knee,...

More from Archive

More from Medtech Insight

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By 

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By 

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By 

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.